KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 73 filers reported holding KINNATE BIOPHARMA INC in Q2 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | – | 127 | 0.0% | 0.00% | – |
| Q2 2023 | $0 | -100.0% | 127 | 0.0% | 0.00% | – |
| Q1 2023 | $1 | 0.0% | 127 | 0.0% | 0.00% | – |
| Q4 2022 | $1 | -100.0% | 127 | 0.0% | 0.00% | – |
| Q3 2022 | $2,000 | 0.0% | 127 | 0.0% | 0.00% | – |
| Q2 2022 | $2,000 | +100.0% | 127 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | -50.0% | 127 | 0.0% | 0.00% | – |
| Q4 2021 | $2,000 | – | 127 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $60,447,769 | 31.36% |
| Vida Ventures Advisors, LLC | 2,207,772 | $13,798,575 | 18.88% |
| Lynx1 Capital Management LP | 2,214,250 | $13,839,063 | 11.54% |
| Foresite Capital Management V, LLC | 1,975,001 | $12,343,756 | 9.12% |
| Nextech Invest Ltd. | 2,329,480 | $14,559,250 | 6.08% |
| Ally Bridge Group (NY) LLC | 109,393 | $683,706 | 0.90% |
| Orbimed Advisors | 5,143,629 | $32,147,681 | 0.63% |
| RA Capital Management | 4,264,144 | $26,650,900 | 0.60% |
| Novo Holdings A/S | 815,707 | $5,098,169 | 0.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $3,112,506 | 0.33% |